What is it about?

We report here the bioanalytical methods that were developed and validated to simultaneously quantify AZD3293, a novel BACE1 inhibitor in late-stage development for Alzheimer's disease, and its major metabolite AZ13569724, and also report data on the adsorption potential for AZD3293 in the collection apparati for cerebrospinal fluid.

Featured Image

Read the Original

This page is a summary of: Simultaneous Quantitation of The Bace1 Inhibitor Azd3293 and its Metabolite Az13569724 in Human Matrices by LC–MS/MS, Bioanalysis, April 2017, Taylor & Francis,
DOI: 10.4155/bio-2017-0003.
You can read the full text:

Read

Contributors

Be the first to contribute to this page